Academic gerontology group built a recurring Khavinson reorder line for a 3-year cross-validation programme

Challenge

The group's Principal Investigator was launching a 3-year cross-validation programme on the Khavinson bioregulator framework, aimed at independent replication of the major Russian-school tissue-specific bioregulator findings in a Western academic context. The programme required all eight Khavinson family members, matching batch COAs, and a separately defined sequence-verification scope for the close-mass family members, plus the kind of literature-pointer support a Western academic group needs when the primary references are Russian-language sources.

Approach

Lyochem's atelier scoped the recurring-order programme across all eight Khavinson SKUs (Adamax, Cortagen, Cartalax, Cardiogen, Bronchogen, Crystagen, Prostamax, Vesugen plus Epithalon as the cross-listed longevity-category member), reserved synthesis capacity against a 12-month forward forecast, and defined the close-mass sequence-verification work, methods, acceptance rules, reporting, and cost before quotation. Matching batch COAs remained the primary lot records.

Outcome

All eight Khavinson SKUs cleared the lab's QC qualification in the first delivery cycle. The 12-month forecast carried the programme through year one without lead-time complaints, and the reservation has been renewed for year two. The lab's published interim findings have referenced Lyochem as the bulk-active supplier with documented sequence-verification on each lot — a methodology disclosure the gerontology journal flagged as essential for the Khavinson replication context.